期刊文献+

三阴性乳腺癌的临床病理特点及预后因素分析 被引量:4

Clinical pathologic characteristics and prognosis factors in patients with triple-negative breast cancer
原文传递
导出
摘要 目的探讨三阴性乳腺癌患者的临床病理特点、分子生物学特性、生存率以及影响预后的因素。方法回顾性分析44例三阴性乳腺癌患者的病历资料,分析其临床病理特点、分子生物学指标和各种治疗方式对生存的影响。结果全组44例患者均为女性,占同期收治乳腺癌患者的7.0%,中位年龄49岁(35-82岁)。其中,浸润性导管癌31例(70.5%),单纯癌6例(13.6%),髓样癌3例(6.8%),管状腺癌2例(4.5%),导管内癌2例(4.5%)。Ⅰ期患者6例(13.6%),Ⅱ期19例(43.2%),Ⅲ期17例(38.6%),Ⅳ期2例(4.5%)。核分级Ⅰ级6例(13.6%),Ⅱ级15例(34.1%),Ⅲ级23例(52.3%)。伴有脉管瘤栓22例(50%),伴有神经浸润10例(22.7%)。中位生存时间4.0年(1.5-8.5年)。单因素分析结果显示,影响总生存的因素为肿瘤大小、淋巴结状态、临床分期、脉管瘤栓和神经浸润。多因素分析结果显示,肿瘤大小和淋巴结状态是影响预后的独立因素。3年总生存率是66.7%。结论三阴性乳腺癌发病率较低,组织学分级较高,多为浸润性导管癌,易较早出现复发和转移。影响总生存的因素为肿瘤大小、淋巴结状态、临床分期、脉管瘤栓和神经浸润,其中影响预后的独立因素是肿瘤大小和淋巴结状态。 Objective To analyze the clinicopathological features,parameters of molecular biology,survival rate,and prognostic factors in triple-negative breast cancer patients.Methods The data of 44 triple-negative breast cancer patients between February 2002 and June 2007 in our institution were retrospectively analyzed.Clinicopathological characteristics,parameters of molecular biology and overall survival rate were surveyed.Results Of all breast cancer patients registered in our institution during this period,these 44 triple-negative breast cancer accounted for 7. 0% with a median age of 49 years (35 - 82years). The pathologi- cal types were infitrating ductal carcinoma ( 70. 5 % ), simple carcinoma ( 13. 6% ), mye carcinoma ( 6. 8% ), tubular adenocarcinoma(4. 5% ) ,intraductal carcinoma(4. 5% ). The stages included stage-Ⅰ 13.6%, stage-Ⅱ 43.2%, stage-Ⅲ38.6% and stage-Ⅳ 4. 5%. The patients with vaseular invasion accounted for 50%, and with nerve invasion accounted for 22. 7%. The median survival time was 4. 0 years( 1.5-8. 5 years). The factors which were found to compromise overall survival were tumor size, lymph node status, clinical stage, vascular invasion and nerve invasion in the univariate analysis. Tumor size and lymph node status were found to be independent prognostic factors for overall survival in the multivariate analysis. The 3-year overall survival rate was 66. 7%. Conclusion Patients with triple-negative breast cancer had low incidence rates, high histological grade and high rate of local and systemic relapse. The maior pathological type was infitratinK ductal carcinoma. The factors which were found to compromise overall survival were turner size, lymph node status, clini- cal stage, vascular invasion and nerve invasion in the univariate analysis. Tumor size and lymph node status were found to be independent prognostic factors for overall survival in the multivariate analysis.
作者 张捷 李丽
出处 《中国肿瘤临床与康复》 2009年第5期392-395,共4页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 乳腺肿瘤 临床病理特点 预后因素 Breast neoplasms Clinicopathologic characteristics Prognostic factors
  • 相关文献

参考文献14

  • 1Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor ( ER ) -negative, progesterone receptor ( PR ) - negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype : A population-based study from the California Cancer Registry[ J]. Cancer, 2007,109 (9) : 1721-1728. 被引量:1
  • 2Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [ J ]. JAMA, 2006,295 ( 21 ) :2492-2502. 被引量:1
  • 3Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence [ J ]. Clin Cancer Res, 2007,13(15 Pt 1) :4429-4434. 被引量:1
  • 4Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early- stage breast cancer [ J ]. J Clin Oncol, 2006,24 ( 36 ) : 5652- 5657. 被引量:1
  • 5Rakha EA, El-Sayed ME, Green AR. Prognostic markers in triplenegative breast cancer[ J]. Cancer, 2007, 109( 1 ) :25. 被引量:1
  • 6Hallmarks of ‘BRCAness' in sporadic cancers [ J ]. Nat Rev Cancer,2004,4(10) :814-849. 被引量:1
  • 7Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implication of the basal-like ( cyclin E high/p27 low/p53 +/glomeruloid-microvascular-proliferation + ) phenotype of BRCAI-related breast cancer[ J]. Cancer Res, 2004,64(3 ) :830-835. 被引量:1
  • 8Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol, 2008,26(8) :1275-1281. 被引量:1
  • 9Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes [ J ]. Clin Cancer Res, 2007,13 (8) :2329-2334. 被引量:1
  • 10Brown M, Tsodikov A, Bauer KR, et al. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004 [ J]. Cancer, 2008,112(4) :737-747. 被引量:1

同被引文献31

  • 1闫成.三阴性乳腺癌的临床研究进展[J].医学信息(下旬刊),2013,26(10):694. 被引量:2
  • 2Liedtke C,Mazouni C,Hess KR,et al.Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J] .J Clin Oncol,2008,26 (8):1275-1281. 被引量:1
  • 3Guix M,Granja Nde M,Meszoely I,et al.Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers[J] .J Clin Onco1,2008,26(6):897-906. 被引量:1
  • 4Tischkowitz M,Brunet JS,Bégin LR,et al.Use of immunohistochemical markers can refine prognosis in triple negative breast cancer[J] .BMC Cancer,2007,17 (7):134. 被引量:1
  • 5Falo C,Moreno A,Varela M,et al.Human epidermal growth factor recepor 2/neu status and response to CMF:retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy[J] .J Cancer Res Clin Oncol,2007,133(7):423-429. 被引量:1
  • 6Dent R,Trudeau M,Pritchard KI.Triple-negative breast cancer:clinical features and patterns of recurrence[J] .Clin Cancer Res,2007,6(13):4429-4434. 被引量:1
  • 7Liedtke C,Mazouni C,Hess KR,et al. Response to neoadjuvant therapy and long-term survival in patients with trlple-negative breast cancer. J Clin Oncol,2008, 26(8):1275-1281. 被引量:1
  • 8Guix M,Granja Nde M,Meszoely I,et al.Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor- positive breast cancers.J Chn Oncol,2008,26(6):897-906. 被引量:1
  • 9Marc Tischkowitz,Jean-Sebastien Brunet,Louis R Begin.Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer, 2007,7: 134. 被引量:1
  • 10袁中玉,王树森,高岩,苏争艳,罗文标,管忠震.305例三阴乳腺癌患者的临床特征及预后因素分析[J].癌症,2008,27(6):561-565. 被引量:161

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部